Combined metabolic activators to treat mitochondrial dysfunction

Mitochondrial dysfunction is a common feature of many human diseases and is emerging as a therapeutic target. 

Systems biology and multiomics approaches have revealed that deficits in glutathione and NAD+ metabolism, impaired fatty acid oxidation, and disrupted redox balance are key drivers of disease pathogenesis.

Combined metabolic activators (CMA) were developed to address these metabolic deficits through the complementary actions of serine, Nacetylcysteine, L-carnitine, and NAD+ precursors.

CMA have been shown to lower hepatic fat, reduce systemic inflammation, accelerate recovery from infection, and improve cognitive performance in clinical studies.

https://www.cell.com/trends/endocrinology-metabolism/fulltext/S1043-2760(26)00034-2

https://sciencemission.com/Targeting-mitochondrial-metabolism